跳至主要内容
临床试验/EUCTR2012-004873-14-DE
EUCTR2012-004873-14-DE进行中(未招募)1 期

PREvention of Macular EDema after cataract surgery - PREMED

niversity Eye Clinic Maastricht0 个研究点目标入组 1,135 人开始时间: 2015年3月6日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
1,135

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • All patients undergoing routine phakoemulsification.
  • Only one eye per patient will be included in the study.
  • Patients should be able to communicate properly and understand
  • instructions.
  • All patients must accept possible off-label use of study medication
  • before inclusion in this study.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 208
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 927

排除标准

  • Study procedures will be different for diabetic and non-diabetic patients.
  • Therefore, the exclusion criteria will also be different for diabetic and
  • non-diabetic patients.
  • General exclusion criteria for participation in this study are:
  • 1. age below 21 years old
  • 2. participation in another clinical study
  • 3. post-traumatic cataract
  • 4. combined surgery
  • 5. functional monoculus
  • 6. previous ocular surgery
  • 7. progressive glaucoma with severe visual field defects, use of
  • antiglaucomatous medication or steroid-induced IOP elevation that
  • required IOP-lowering treatmeht
  • 8. IOP > or = 25 mmHg
  • 9. history of intraocular inflammation or uveitis
  • 10. history of pseudoexfoliation syndrome, which is expected to cause
  • peroperative complications
  • 11. history of Fuchs' endothelial dystrophy or cornea guttata 3+
  • 12. hiatory of retinal vein occlusion
  • 13. any macular pathology that might affect visual acuity, other than
  • diabetic macular edema
  • 14. use of intravitreal bevacizumab or ranibizumab in the previous 6
  • weeks or intravitreal aflibercept in the previous 10 weeks
  • 15. use of intra- or periocular corticosteroid injection in the previous 4
  • 16. current use of topical NSAIDs or corticosteroids
  • 17. use of systemic corticosteroids (> or = 20 mg prednisolone or
  • equivalence)
  • 18. history of relevant adverse events, including serious adverse events
  • (SAE), occuring after administration of NSAIDs, acitylsalicylic acid,
  • sodium sulphite, corticosteroids or bevacizumab
  • 19. contraindications for use of topical corticosteroids or intravitreal
  • bevacizumab or related drugs
  • Non-diabetic patients with a history of CME will be excluded from
  • participation in the study.
  • Additionally, diabetic patients will be excluded from participation in case
  • 1. macular edema with a CSMT > or = 450 µm
  • 2. very severe NPDR or proliferative DR requiring panretinal
  • photocoagulation or vitrectomy
  • 3. vitreous hemorrhage present during preoperative visit(s)
  • 4. cerebrovascular incident, myocardial infarction or other
  • thromboembolic events in the previous 3 months
  • 5. a history of recurrent thromboembolic events
  • 6. a history of severe systemic bleeding in the previous 3 months
  • 7. major surgery in the previous 3 months
  • 8. history of glaucoma

研究者

发起方
niversity Eye Clinic Maastricht

相似试验